Trial Profile
PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PERCIST; RESIST-PC
- Sponsors Endocyte
- 01 Mar 2021 Status changed to discontinued.(Recruitment was stopped before the target sample size was achieved).
- 31 May 2020 Results of post hoc analysis assessing overall survival (OS) in a single-study site cohort (UCLA) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 05 May 2020 Status changed from active, no longer recruiting to completed.